Janssen has announced the launch of INVOKANA® (canagliflozin) in the UK, a new Type 2 diabetes treatment shown to reduce blood sugar levels in people for whom diet and lifestyle measures or treatment with other blood sugar-lowering medicines, do not provide adequate control.1In parallel with today's launch, canagliflozin has also received a preliminary positive recommendation from the National Institute for Health and Care Excellence (NICE), as a treatment option for adults with Type 2 diabetes.
No comments:
Post a Comment